SLC5A2 and Hypoglycemia: This confirms that mild inhibition of CYP2C9 by canagliflozin (IC50 = 80 μM) does not translate into a clinically important effect on glyburide metabolism, indicating that SGLT2 inhibitors can be safely added to sulfonylurea therapy without altering the pharmacokinetic or metabolic profile of sulfonylureas, although the additive pharmacodynamic effects on blood glucose and hypoglycemia risk still require monitoring.